About: Jørgen Jespersen

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Jørgen Jespersen Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
field of work	wds:Q63927652-28787D93-B63A-4708-B78F-42DA821CE451 wds:Q63927652-52EAA9C1-D565-4753-AF16-000824B9E589 wds:Q63927652-9E6008B8-657A-4476-B66F-2EF13D5F2850 wds:Q63927652-B8FF1BA1-C866-4C53-B7A9-A5C2128ED11C wds:Q63927652-C0542DC5-214E-46DF-90BB-C8E3F584F808
field of work	chemistry cardiovascular disease thrombosis biochemistry clinical biochemistry
description	researcher (en) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідник (uk) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy) Dánský biochemik, zaměřuje se na výzkum trombózy. (cs)
rdfs:label	Jørgen Jespersen (en) J Jespersen (es) J Jespersen (nl) J Jespersen (ast) Jørgen Jespersen (cs) Jørgen Jespersen (de)
skos:prefLabel	Jørgen Jespersen (en) J Jespersen (es) J Jespersen (nl) J Jespersen (ast) Jørgen Jespersen (cs) Jørgen Jespersen (de)
name	Jørgen Jespersen (en) J Jespersen (es) J Jespersen (nl) J Jespersen (ast) Jørgen Jespersen (cs) Jørgen Jespersen (de)
Scopus author ID	wds:Q63927652-9F5CD168-98BF-4F8B-8F1E-81436334E8E1
Scopus author ID	7102111742
given name	wds:Q63927652-FABC0C3C-0051-49AD-A011-E78BE2010FFD
given name	Jørgen
instance of	wds:Q63927652-D55AAB76-94C9-426F-9B0F-998EAD45C560
NL CR AUT ID	wds:Q63927652-7BCBF709-820D-4D44-A075-E6F6C771B2B2
instance of	Homo sapiens
NL CR AUT ID	xx0308513
occupation	wds:Q63927652-583E7A05-C679-499E-8C16-B7D9A0E352D6
employer	wds:Q63927652-2B9DEAD9-DD6A-41F8-8D10-B247A7B7CC89 wds:Q63927652-94EEF667-E1A2-464A-BE3E-CC0C5368635C
languages spoken, written or signed	wds:Q63927652-95FCBB63-1091-4B10-B3AD-5E2FDA74385E wds:Q63927652-CCC45E27-02D0-4066-997D-A9E9F7C282C1
sex or gender	wds:Q63927652-B3185C88-E21C-4348-A15E-73F1C026D642
official website	wds:Q63927652-D6A005D7-0D9E-4758-874B-673E29813158
occupation	researcher
employer	Odense University University of Southern Denmark
languages spoken, written or signed	English Danish
sex or gender	male
official website	https://portal.findresearcher.sdu.dk/en/persons/b95f09d8-f647-43e3-b6dd-f6919b2ab0cc
ORCID iD	wds:Q63927652-60AFB0AE-9C1C-4330-A7E4-5D02E6F2F442
ORCID iD	https://orcid.org/0000-0002-3059-2356
ORCID iD	0000-0002-3059-2356
is owl:sameAs of	Jørgen Jespersen
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q63927652
is author of	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. Genetic Influence on Inflammation Variables in the Elderly New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases Multicentre evaluation of commercial kit methods: plasminogen activator inhibitor activity. DNA-polymorphisms and plasma levels of vascular disease risk factors in Greenland Inuit--is there a relation with the low risk of cardiovascular disease in the Inuit? The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease Longevity is independent of common variations in genes associated with cardiovascular risk Factor VII-activating protease in patients with acute deep venous thrombosis. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Inflammation, thrombosis and atherosclerosis: results of the Glostrup study. Lipoprotein profile of a Greenland Inuit population. Influence of anthropometric variables, Apo E and A4 polymorphism, and lifestyle General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy--a prospective, randomized, double-blind, placebo-controlled study Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patients Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study Influence of plasma platelets on activated protein C resistance assay The clinical evaluation of International Normalized Ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. Activity of recombinant factor VIIa under different conditions in vitro: effect of temperature, pH, and haemodilution. Anticoagulants in heart disease: current status and perspectives Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Antithrombin-III and Platelets in Haemodialysis Patients A study of the conditions and accuracy of the thrombin time assay of plasma fibrinogen Fasting blood coagulation and fibrinolysis of young adults unchanged by reduction in dietary fat content Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Gender Differences in Fibrin Polymerization and Lysability of Fibrin in Patients with Atrial Fibrillation. A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel. Plasma factor VII-activating protease is increased by oral contraceptives and induces factor VII activation in-vivo Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software